Developer docs
API playgroundTry for free, no card

Search company profiles

Cure HHT Canada

Full company profile

uuid00ydyp3

Namestring
Cure HHT Canada
Legal namestring
Cure HHT Canada
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Cure HHT Canada is a registered Canadian charity (CRA Business No. 720915149 RC0001) headquartered in Vancouver, BC, that provides education, support, advocacy, and research funding for individuals and families affected by hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder affecting approximately 1 in 5,000 people worldwide. The organization was launched in 2026 as a standalone national entity built in collaboration with the international Cure HHT organization, formalizing relationships with five HHT Centers of Excellence (Edmonton, Vancouver, Winnipeg, Toronto, Montreal) and two certified genetic testing laboratories (Impact Genetics and the Hospital for Sick Children's Molecular Genetics Laboratory). Its primary audiences are undiagnosed or diagnosed HHT patients and their families, alongside Canadian clinicians seeking specialized training, with the latter addressed through clinician scholarships and curated webinar content featuring experts including Dr. Marie Faughnan and Dr. Krings.

The organization's product surface is digital and educational rather than commercial. Core offerings include the Epistaxis Severity Score (ESS) online tool (a six-question 0-10 scoring instrument hosted at hhtess.com that helps clinicians monitor HHT nosebleed severity), the HHT Outcomes Registry (a patient-consented data repository feeding into the $131,000 Dartmouth Geisel School of Medicine-backed North American HHT Database), downloadable HHT brochures, and a recurring webinar and virtual-conference program (e.g., 2021/2023 Virtual Patient Conferences, Eastern Canada HHT Patient Conference, 2026 Brain AVMs webinar series). Distribution is purely self-serve via curehhtcanada.com (English/French), supplemented by YouTube, Facebook, LinkedIn, and email/newsletter channels — no commercial channels, no APIs, and no native mobile app.

Revenue mechanics are entirely philanthropic. Cure HHT Canada accepts donations through the Classy.org platform and e-Transfers to donations@curehhtcanada.org; funds are directed toward Canadian HHT education, awareness, research, conference support, and clinician scholarships, plus global research collaborations through Cure HHT. No pricing models, commercial contracts, or enterprise revenue exist, and the organization is structurally exempt from revenue concentration but correspondingly dependent on donor sentiment, charitable giving cycles, and grant availability. Leadership is a volunteer board (President Jane Wace; Vice President Donald Hutchinson; Secretary Izabela Veljkovic; Member-at-Large Kris Li; Medical Advisory Board Dr. Marie E. Faughnan) supported by Cure HHT shared services.

Short descriptiontext

Cure HHT Canada is a Vancouver-based registered Canadian charity that delivers education, advocacy, genetic-testing navigation, and research funding for individuals and families affected by hereditary hemorrhagic telangiectasia, partnering with five HHT Centers of Excellence across Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease advocacy, patient education resources, HHT awareness, research funding support, community health support
Industry1 code
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Other Individual and Family Services624190
SIC code2 codes
  • Services-Social Services8300
  • Services-Misc Health & Allied Services, Nec8090
Product category
Patient Advocacy and Rare Disease Support
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Charitable Donations
TypeGrants Donations
Description

Cure HHT Canada operates as a registered Canadian charity (CRA Registered Charity Business No. 720915149 RC0001). The organization raises funds through donations via their website (Classy.org platform) and e-Transfers to donations@curehhtcanada.org. Donations support HHT research, education, awareness, and care improvement in Canada.

curehhtcanada.com
2Donor-Specified Contributions
TypeGrants Donations
Description

Canadian donations are directed to fund local education, awareness, research, and global HHT research initiatives. The organization also sponsors young Canadian scholars, supports Canadian conferences and education sessions, and funds HHT Centers of Excellence certification expansion.

curehhtcanada.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Cure HHT Canada is a registered Canadian charity that supports individuals and families affected by hereditary hemorrhagic telangiectasia (HHT) through patient education, awareness campaigns, webinars and conferences, downloadable resources (including the HHT Brochure and the Epistaxis Severity Score tool), and funding for HHT research such as the HHT Outcomes Registry. It connects patients with five Canadian HHT Centers of Excellence and works in collaboration with Cure HHT.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • HHT affects 1 in 5000 people; estimated 80% remain undiagnosed - organization's work focuses on improving diagnosis rates through awareness
+2 more records
Product overview1 text field

Cure HHT Canada is a charity organization that serves as a hub for HHT awareness and education across Canada. The organization offers several digital and educational products including the Epistaxis Severity Score (ESS) online tool for evaluating nosebleed severity, the HHT Outcomes Registry for patient data collection and research, downloadable educational brochures, and webinar/conference programs. These products work together to support HHT diagnosis, treatment monitoring, patient education, and research advancement for the Canadian HHT community.

Product and service5 records
1Epistaxis Severity Score (ESS) Tool
CategoryPatient Assessment Tool
Description

An online tool that evaluates the current severity of HHT patient nosebleeds by computing a 0-10 score from six simple questions, helping healthcare providers assess patient response to treatment. Targeted at HHT patients and their clinicians.

2HHT Outcomes Registry
CategoryResearch Registry
Description

A research registry that gathers detailed clinical, radiographic, genetic, and treatment information on consenting HHT patients across North America to advance research and enable connection with therapeutic trials. Aimed at HHT patients and the research community.

3HHT Brochure
CategoryEducational Material
Description

A printable downloadable PDF brochure that provides critical information about HHT, including resources for testing and treatment. Targeted at newly diagnosed patients, families, and the broader HHT community.

4HHT Webinar Series
CategoryEducational Programming
Description

An ongoing educational webinar series covering HHT topics including brain AVMs imaging and management, GI bleeding, nosebleeds, pediatric care, pregnancy, and emerging therapies, presented by HHT medical experts. Aimed at patients, families, and clinicians.

5Virtual Patient Conference
CategoryEducational Programming
Description

A multi-speaker virtual conference in which HHT medical professionals and scientists deliver educational lectures to HHT patients and families. Held in 2021 and 2023, with in-person Eastern Canada HHT Patient Conferences also organized in Toronto.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-26
Description

Cure HHT Canada was launched in partnership with Cure HHT, the leading international HHT advocacy organization with over 30 years of experience. Cure HHT worked closely with Cure HHT Canada's board over the past year to support the organization's growth and readiness. Cure HHT Canada now serves as the national voice for the Canadian HHT community while collaborating on the shared mission of improving lives and accelerating progress for everyone affected by HHT.

2Edmonton HHT Centre (University of Alberta)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of five HHT Centers of Excellence across Canada. Located at University of Alberta, 105C Clinical Sciences Building, 11350-83 Ave, Edmonton, AB T6G 2B7. Directors: Dr. Dilini Vethanayagam, Dr. Richard Owen.

curehhtcanada.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of five HHT Centers of Excellence across Canada. Led by Dr. Amin Javer (Sinus Centre) and Dr. Scott Apperley (Respirologist). Located at St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC V6Z 1Y6.

4Winnipeg HHT Centre (Grace Hospital)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of five HHT Centers of Excellence across Canada. Located at Grace Hospital AMC, 300 Booth Drive, Winnipeg, MB R3J 3M7. Director: Dr. Els Maria De Gussem.

curehhtcanada.com
5Toronto HHT Centre (St. Michael's Hospital)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of five HHT Centers of Excellence across Canada and the only HHT clinic in Canada at one time. Located at 30 Bond St., Room 6049, Toronto, ON M5B 1W8. Director: Dr. Marie Faughnan. This is a key center for genetic testing, screening, and treatment of HHT patients across Canada.

curehhtcanada.com
6Montreal HHT Centre (CHUM)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of five HHT Centers of Excellence across Canada. Located at CHUM, 264 René-Lévesque East, 2nd floor, Montreal, QC H2X 1P1. Director: Dr. Andreanne Gauthier.

curehhtcanada.com
7BioInformatics Service Center at Dartmouth's Geisel School of Medicine
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Awarded a $131,000 grant for the development of a North American HHT Database. The database gathers de-identified clinical, radiographic, genetic, and treatment information on HHT patients evaluated at HHT Centers of Excellence. This registry supports pharmaceutical investment in HHT drug development.

curehhtcanada.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Certified genetic testing center for HHT serving all of Canada (excluding Ontario). Located at 115 Midair Court, Brampton, Ontario L6T 5V1. Provides genetic testing for HHT diagnosis and family screening.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Certified genetic testing center for HHT serving Ontario. Located at 555 University Ave., Roy C. Hill Wing Rm. 3-421, Toronto, ON M5G 1X8. Provides genetic testing for HHT diagnosis in Ontario.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cure HHT Canada

Patient Advocacy and Rare Disease Supportcurehhtcanada.com

Cure HHT Canada is a Vancouver-based registered Canadian charity that delivers education, advocacy, genetic-testing navigation, and research funding for individuals and families affected by hereditary hemorrhagic telangiectasia, partnering with five HHT Centers of Excellence across Canada.

What Cure HHT Canada does

Cure HHT Canada is a registered Canadian charity (CRA Business No. 720915149 RC0001) headquartered in Vancouver, BC, that provides education, support, advocacy, and research funding for individuals and families affected by hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder affecting approximately 1 in 5,000 people worldwide. The organization was launched in 2026 as a standalone national entity built in collaboration with the international Cure HHT organization, formalizing relationships with five HHT Centers of Excellence (Edmonton, Vancouver, Winnipeg, Toronto, Montreal) and two certified genetic testing laboratories (Impact Genetics and the Hospital for Sick Children's Molecular Genetics Laboratory). Its primary audiences are undiagnosed or diagnosed HHT patients and their families, alongside Canadian clinicians seeking specialized training, with the latter addressed through clinician scholarships and curated webinar content featuring experts including Dr. Marie Faughnan and Dr. Krings.

The organization's product surface is digital and educational rather than commercial. Core offerings include the Epistaxis Severity Score (ESS) online tool (a six-question 0-10 scoring instrument hosted at hhtess.com that helps clinicians monitor HHT nosebleed severity), the HHT Outcomes Registry (a patient-consented data repository feeding into the $131,000 Dartmouth Geisel School of Medicine-backed North American HHT Database), downloadable HHT brochures, and a recurring webinar and virtual-conference program (e.g., 2021/2023 Virtual Patient Conferences, Eastern Canada HHT Patient Conference, 2026 Brain AVMs webinar series). Distribution is purely self-serve via curehhtcanada.com (English/French), supplemented by YouTube, Facebook, LinkedIn, and email/newsletter channels — no commercial channels, no APIs, and no native mobile app.

Revenue mechanics are entirely philanthropic. Cure HHT Canada accepts donations through the Classy.org platform and e-Transfers to donations@curehhtcanada.org; funds are directed toward Canadian HHT education, awareness, research, conference support, and clinician scholarships, plus global research collaborations through Cure HHT. No pricing models, commercial contracts, or enterprise revenue exist, and the organization is structurally exempt from revenue concentration but correspondingly dependent on donor sentiment, charitable giving cycles, and grant availability. Leadership is a volunteer board (President Jane Wace; Vice President Donald Hutchinson; Secretary Izabela Veljkovic; Member-at-Large Kris Li; Medical Advisory Board Dr. Marie E. Faughnan) supported by Cure HHT shared services.

Cure HHT Canada firmographics

Firmographics
Name
Cure HHT Canada
Legal name
Cure HHT Canada
Website
https://curehhtcanada.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
1–10 employees
Short description
Cure HHT Canada is a Vancouver-based registered Canadian charity that delivers education, advocacy, genetic-testing navigation, and research funding for individuals and families affected by hereditary hemorrhagic telangiectasia, partnering with five HHT Centers of Excellence across Canada.
Ownership category
akta.pro rank

Cure HHT Canada industry classification

Industry
Product category
Patient Advocacy and Rare Disease Support
NAICS
Voluntary Health Organizations (813212), Other Individual and Family Services (624190)
SIC
Services-Social Services (8300), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)

Keywords

  • Rare disease advocacy
  • Patient education resources
  • HHT awareness
  • Research funding support
  • Community health support

Where Cure HHT Canada is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Cure HHT Canada business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Charitable Donations: Cure HHT Canada operates as a registered Canadian charity (CRA Registered Charity Business No. 720915149 RC0001). The organization raises funds through donations via their website (Classy.org platform) and e-Transfers to donations@curehhtcanada.org. Donations support HHT research, education, awareness, and care improvement in Canada.
  2. Donor-Specified Contributions: Canadian donations are directed to fund local education, awareness, research, and global HHT research initiatives. The organization also sponsors young Canadian scholars, supports Canadian conferences and education sessions, and funds HHT Centers of Excellence certification expansion.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Cure HHT Canada product offering

Product offering

Core offering

Cure HHT Canada is a registered Canadian charity that supports individuals and families affected by hereditary hemorrhagic telangiectasia (HHT) through patient education, awareness campaigns, webinars and conferences, downloadable resources (including the HHT Brochure and the Epistaxis Severity Score tool), and funding for HHT research such as the HHT Outcomes Registry. It connects patients with five Canadian HHT Centers of Excellence and works in collaboration with Cure HHT.

Product overview

Cure HHT Canada is a charity organization that serves as a hub for HHT awareness and education across Canada. The organization offers several digital and educational products including the Epistaxis Severity Score (ESS) online tool for evaluating nosebleed severity, the HHT Outcomes Registry for patient data collection and research, downloadable educational brochures, and webinar/conference programs. These products work together to support HHT diagnosis, treatment monitoring, patient education, and research advancement for the Canadian HHT community.

Differentiator

Problem solved

Functional benefit

Products and services

  • Epistaxis Severity Score (ESS) Tool An online tool that evaluates the current severity of HHT patient nosebleeds by computing a 0-10 score from six simple questions, helping healthcare providers assess patient response to treatment. Targeted at HHT patients and their clinicians.
  • HHT Outcomes Registry A research registry that gathers detailed clinical, radiographic, genetic, and treatment information on consenting HHT patients across North America to advance research and enable connection with therapeutic trials. Aimed at HHT patients and the research community.
  • HHT Brochure A printable downloadable PDF brochure that provides critical information about HHT, including resources for testing and treatment. Targeted at newly diagnosed patients, families, and the broader HHT community.
  • HHT Webinar Series An ongoing educational webinar series covering HHT topics including brain AVMs imaging and management, GI bleeding, nosebleeds, pediatric care, pregnancy, and emerging therapies, presented by HHT medical experts. Aimed at patients, families, and clinicians.
  • Virtual Patient Conference A multi-speaker virtual conference in which HHT medical professionals and scientists deliver educational lectures to HHT patients and families. Held in 2021 and 2023, with in-person Eastern Canada HHT Patient Conferences also organized in Toronto.

Quantifiable outcome

  • HHT affects 1 in 5000 people; estimated 80% remain undiagnosed - organization's work focuses on improving diagnosis rates through awareness
  • +2 more outcomes

Companies that use Cure HHT Canada

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Cure HHT Canada technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Cure HHT Canada partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and major.

  • Cure HHT (Parent Organization)coreStrategic or Co-development Partner · 26 June 2026Cure HHT Canada was launched in partnership with Cure HHT, the leading international HHT advocacy organization with over 30 years of experience. Cure HHT worked closely with Cure HHT Canada's board over the past year to support the organization's growth and readiness. Cure HHT Canada now serves as the national voice for the Canadian HHT community while collaborating on the shared mission of improving lives and accelerating progress for everyone affected by HHT.
  • Edmonton HHT Centre (University of Alberta)coreStrategic or Co-development PartnerOne of five HHT Centers of Excellence across Canada. Located at University of Alberta, 105C Clinical Sciences Building, 11350-83 Ave, Edmonton, AB T6G 2B7. Directors: Dr. Dilini Vethanayagam, Dr. Richard Owen.
  • Vancouver HHT Centre (St. Paul's Hospital)coreStrategic or Co-development PartnerOne of five HHT Centers of Excellence across Canada. Led by Dr. Amin Javer (Sinus Centre) and Dr. Scott Apperley (Respirologist). Located at St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC V6Z 1Y6.
  • Winnipeg HHT Centre (Grace Hospital)coreStrategic or Co-development PartnerOne of five HHT Centers of Excellence across Canada. Located at Grace Hospital AMC, 300 Booth Drive, Winnipeg, MB R3J 3M7. Director: Dr. Els Maria De Gussem.
  • Toronto HHT Centre (St. Michael's Hospital)coreStrategic or Co-development PartnerOne of five HHT Centers of Excellence across Canada and the only HHT clinic in Canada at one time. Located at 30 Bond St., Room 6049, Toronto, ON M5B 1W8. Director: Dr. Marie Faughnan. This is a key center for genetic testing, screening, and treatment of HHT patients across Canada.
  • Montreal HHT Centre (CHUM)coreStrategic or Co-development PartnerOne of five HHT Centers of Excellence across Canada. Located at CHUM, 264 René-Lévesque East, 2nd floor, Montreal, QC H2X 1P1. Director: Dr. Andreanne Gauthier.
  • BioInformatics Service Center at Dartmouth's Geisel School of MedicinemajorStrategic or Co-development PartnerAwarded a $131,000 grant for the development of a North American HHT Database. The database gathers de-identified clinical, radiographic, genetic, and treatment information on HHT patients evaluated at HHT Centers of Excellence. This registry supports pharmaceutical investment in HHT drug development.
  • Impact Genetics Inc.coreStrategic or Co-development PartnerCertified genetic testing center for HHT serving all of Canada (excluding Ontario). Located at 115 Midair Court, Brampton, Ontario L6T 5V1. Provides genetic testing for HHT diagnosis and family screening.
  • The Hospital for Sick Children - Molecular Genetics LaboratorycoreStrategic or Co-development PartnerCertified genetic testing center for HHT serving Ontario. Located at 555 University Ave., Roy C. Hill Wing Rm. 3-421, Toronto, ON M5G 1X8. Provides genetic testing for HHT diagnosis in Ontario.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Cure HHT Canada competitors and assessment

Company assessment

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Cure HHT Canada social profiles

Digital presence

Cure HHT Canada compliance and trust

Trust signal

Compliance1 record

Cure HHT Canada financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cure HHT Canada leadership team

Management profile

Number of profiles

Profiles5 records

Cure HHT Canada funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cure HHT Canada M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cure HHT Canada

What does Cure HHT Canada do?

Cure HHT Canada is a registered Canadian charity that supports individuals and families affected by hereditary hemorrhagic telangiectasia (HHT) through patient education, awareness campaigns, webinars and conferences, downloadable resources (including the HHT Brochure and the Epistaxis Severity Score tool), and funding for HHT research such as the HHT Outcomes Registry. It connects patients with five Canadian HHT Centers of Excellence and works in collaboration with Cure HHT.

Is Cure HHT Canada a public or private company?

Cure HHT Canada is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Cure HHT Canada founded?

Cure HHT Canada was founded in 2026. It employs 1 to 10 people.

Where is Cure HHT Canada based?

Cure HHT Canada is headquartered in Vancouver, Canada, in the North America region.

How does Cure HHT Canada make money?

Two revenue lines are on record. Charitable Donations are the primary driver. The others are donor-Specified Contributions.

Does Cure HHT Canada have an API?

No public API is recorded for Cure HHT Canada.

What industry is Cure HHT Canada in?

Cure HHT Canada's product category is Patient Advocacy and Rare Disease Support. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS). Its NAICS code is 813212 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAtavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic TelangiectasiaAtavistik Bio announced a partnership with the Cure HHT Clinical Trial Network to support clinical development of ATV-1601, an investigational oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia. The first clinical site in the Harmony-HHT Phase 1/2 study has been activated at Massachusetts General Hospital, marking a milestone in the advancement of the program. HHT is a rare inherited bleeding disorder affecting over 80,000 people in the US and 1.6 million globally, with no approved therapies currently available, and ATV-1601 has received FDA Fast Track designation.GlobeNewswireDiagonal Therapeutics to Present Insights from HHT IMPACT, a Natural History Study Initiated in Partnership with Cure HHT, at ASH 2025Diagonal Therapeutics announced it will present interim data from its HHT IMPACT natural history study at the 67th American Society of Hematology Annual Meeting in Orlando, Florida from December 6-9, 2025. The study, conducted in partnership with patient advocacy organization Cure HHT, enrolled 109 adult patients with moderate-to-severe HHT and found that the majority experienced daily nosebleeds, averaging more than 20 bleeding events per month with a mean duration of nearly 20 minutes each. Results from the final analysis, anticipated in 2026, will inform the design of a first-in-human clinical trial for DIAG723, the company's first-in-class disease-modifying treatment for HHT, with enrollment scheduled to begin mid-2026.